Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: MDR-TB

Displaying 29 papers

New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades

Publication: Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis. 2010 Jun;14(6):663-4. http://www.ingentaconnect.com/content/iuatld/ijtld/2010/0000001

6/2010

Tags: Advocacy, Clinical Development, Editorials, MDR-TB, TB Drug Market, TB Market, Trial Design

Global tuberculosis drug development pipeline: the need and the reality

Publication: Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9.

5/2010

Tags: Advocacy, Bedaquiline (TMC-207), Biomarkers, Childhood TB, Clinical Development, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Policy, Pretomanid/PA-824, Rifapentine, Sutezolid, Trial Design

Tuberculosis drug development: Progress, challenges, and the road ahead

Publication: Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb). 2010 May;90(3):162-7. doi: 10.1016/j.tube.2010.03.003.

4/2010

Tags: Advocacy, Clinical Development, Editorials, Global Pipeline, MDR-TB, Policy

Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development

Publication: Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009 Dec;30(4):755-68, ix. doi: 10.1016/j.ccm.2009.08.011.

12/2009

Tags: Advocacy, Clinical Development, Drug Discovery, Editorials, Global Pipeline, MDR-TB, TB-HIV

New tuberculosis therapeutics: a growing pipeline

Publication: Spigelman MK New tuberculosis therapeutics: a growing pipeline. J Infect Dis. 2007 Aug 15;196 Suppl 1:S28-34. http://jid.oxfordjournals.org/content/196/Supplement_1/S28.long. Accessed March 7, 2016

8/2007

Tags: Clinical Development, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pretomanid/PA-824, Rifapentine, TB-HIV

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery

Publication: Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00008?token=00521b85a26b1174e1f7b76504c48662a2

6/2007

Tags: Drug Discovery, Drug Targets, M.tb. Biology, MDR-TB, Preclinical Data

Planning to improve global health: the next decade of tuberculosis control

Publication: Dermot Maher, Chris Dye, Katherine Floyd, et. al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ. 2007 May; 85(5): 341–347. doi: 10.2471/06.037820

5/2007

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB-HIV

Antimycobacterium Agents

Publication: Ma Z, Ginsberg A, Spigelman M. Antimycobacterium Agents. Elsevier, Philadelphia, PA. 2007 Jan; 700-4, 719-20, 26.

1/2007

Tags: Clinical Development, Drug Discovery, Drug Targets, Global Pipeline, M.tb. Biology, MDR-TB, Moxifloxacin, Preclinical Models, Pretomanid/PA-824, Pyrazinamide, Rifapentine, TB-HIV, Trial Design

Joining forces to develop weapons against TB: together we must.

Publication: Freire M, Roscigno G. Joining forces to develop weapons against TB: together we must. Bull World Health Organ. 2002;80(6):429. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567524/pdf/12131997.pdf. Accessed March 7, 2016

1/2002

Tags: Advocacy, Editorials, MDR-TB, Moxifloxacin, Pretomanid/PA-824, TB-HIV

Pages